Neuronetics Inc (STIM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neuronetics Inc   (NASDAQ: STIM)


Neuronetics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Neuronetics Inc's ROI in the second quarter of 2026?
Neuronetics Inc recorded a cumulative net loss of $-31 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -26.83%.

Within the Healthcare sector 209 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3231 to 3435.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -3.14 % 10.75 % 27.11 % 18.66 % 143.92 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 107 106 120 126 117
Return On Investment (TTM) -26.83 % -31.72 % -32 % -38.81 % -40.89 %
STIM's Overall Ranking # 3435 # 3231 # 3217 # 3448 # 3037
Seq. Investment Change TTM -2.03 % -4.04 % 6.4 % -3.17 % 12.03 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -31 -37 -39 -45 -49

STIM Company Profile >> Back to STIM Roi Comparisons >> See Annual STIM Return On Investment



Return On Investment STIM's Ranking
Within: No.
Industry # 65
Sector # 210
Overall # 3435

Return On Investment Statistics
High Average Low
-24.09 %
-44.3 %
-222.1 %
(Jun 30 2026)   (Jun 30 2018)



  News about Neuronetics Inc Return on Investment ROI

HCSC Expands TMS Coverage for Adolescents A Beacon in Mental Health Amid Neuronetics Financial Challenges,

September 25, 2024

Health Care Service Corporation Expands TMS Coverage for Adolescents: A Ray of Hope in Mental Health Amid Challenging ROI for Neuronetics Inc. In a landmark decision that aims to expand access to innovative mental health treatments, Health Care Service Corporation (HCSC), the largest customer-owned health insurer in the United States, has announced an updated policy that includes first-line Transcranial Magnetic Stimulation (TMS) coverage for adolescents. This policy change affects millions of individuals covered by HCSC BlueCross BlueShield policies, providing a new avenue of hope for young people struggling with severe depression and other mental health disorders.As mental health awareness continues to grow across the country, the inclusion of TMS an FDA-approved non-invasive treatment known for its success in treating treatment-resistant depression marks a significant milestone. It is a testament to HCSC’s commitment to addressing the rising tide of mental health issues among adolescents, granting them access to cutting-edge treatment methods previously reserved for adults or those with less robust insurance coverage.

Revolutionizing Depression Treatment: NeuroStar TMS Grabs Expanded Approval, Redefining Hope in Japan }, finish_reaso

December 4, 2023

Technological Advances Streamline and Enhance MDD Treatment: NeuroStar TMS Receives Expanded Regulatory Approval in Japan
In recent news, Neuronetics Inc. has experienced a staggering 42.96% increase in shares following the expanded regulatory approval of their groundbreaking invention, the NeuroStar TMS system, in Japan. This milestone represents a significant step forward in the battle against Major Depressive Disorder (MDD) as it harnesses technological advancements to revolutionize treatment options and enhance patient outcomes.
Major Depressive Disorder is a debilitating mental health condition affecting millions worldwide. Until recently, treatment options often involved a combination of psychotherapy and medication. While effective for many, it is a well-known fact that MDD patients do not always respond to these conventional methods. This has led to a growing need for more innovative and efficient treatments.





Financial Statements
Neuronetics Inc's II. Quarter Investments $ 107 Millions STIM's Balance sheet
Neuronetics Inc's II. Quarter Income $ -3 Millions Quarterly STIM's Income Statement
STIM's Income by Division See STIM's Income by Division


STIM Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 96 91 94 81 122
Y / Y Investment Growth 5.4 % -2.81 % 16.05 % -33.83 % 97.21 %
Net Income in Millions -39 -44 -30 -37 -31
Y / Y Net Income Growth - - - - -
Annual Return On Investment -40.78 % -48.03 % -32.23 % -46.04 % -25.57 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
STIM's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for STIM's Competitors
Subscribers only: Roi for Neuronetics Inc's Suppliers
Subscribers only: Return On Investment for STIM's Customers

Other Ratios
STIM's Roa STIM's Inventory Turnover Ratio STIM's Growth Rates STIM's Dividend Statistics
STIM's Profitability Ratios STIM's Asset Turnover Ratio STIM's Dividend Growth
STIM's Roe STIM's Valuation Ratios STIM's Financial Strength Ratios STIM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:23:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.